Elron Ventures Ltd · TASE:ELRN
Elron Ventures — Investor Presentation (November 2012)
25 slides from Elron Ventures's investor presentation, November 2012
Slide 1: Investors Presentation Elron
A .. xi Investors Presentation ELRON November 2012
Slide 2: Forward-Looking Information
Forward-Looking Information This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the fe
Slide 3: Q3 2012 highlights: Given Imaging, RDC, dividend, cash
GIVEN IMAGING: Net income increased 58% to $6.0 million, compared to $3.8 million in the same quarter of last year. GIVEN IMAGING plans to submit the PillCam COLON 2 capsule for FDA clearance by the end of the year. RDC, Elron’s and Rafael’s jointly held subsidiary, signed a term sheet for the
Slide 4: Major Exits: ~$400m in the last three years
MAJOR EXITS > During the last three years Elron led exits amounting to ~$400m in the aggregate Sale of company to Roche for $179m Sale of holdings to Discount Investment Sale of company to Corp and Clal Industries Sale of company to Enablence for $50m and Investments for Alvarion for $30m $60m Sale
Slide 5: Elron Med Tech: invested in med-tech companies in the last 5 years
ELRON > MED TECH invested in med-tech companies during the last 5 years
Slide 6: Group Companies / Med-Tech
ELRON > MED TECH GROUP COMPANIES / MED-TECH:
Slide 7: The Way We Work: Active Management
THE WAY WE WORK > ACTIVE MANAGEMENT FOCUS on investments in which we can exert significant influence and take an active role in their management. LEVERAGE KNOW-HOW, EXPERTISE, AND NETWORK of global partners to identify and realize opportunities. SEEK A LEAD SHAREHOLDER POSITION in core assets
Slide 8: Main Investments 2011-2012
MAIN INVESTMENTS 2011 -2012>
Slide 9: Group Companies Overview
GROUP COMPANIES OVERVIEW
Slide 10: BrainsGate: device for treating ischemic stroke
Elron’s holding: 30% Device for treating ischemic stroke in 24 hour window post symptom onset, as opposed to treatment with the tPA protein which is only approved for use during a window that lasts just several hours Electrical stimulation of SPG (a nerve center located behind the nasal cavity
Slide 11: Direct cost of strokes in the US
The direct cost of strokes in the US amounted to billion in 2010 Sources: World Health Organization website: http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf. American Heart Association: Heart Disease and Stroke Statistics – 2010 Update.
Slide 12: BrainsGate expects to complete the clinical trial during 2013
BrainsGate conducted a clinical trial on approximately 300 patients, whose results strengthen the assessment that BrainsGate’s treatment has a considerable clinical effect, which is stronger than the effect found in current treatments. Since June 2011, BrainsGate has been enrolling patients in a
Slide 13: Pocared: automated system for infectious disease diagnosis
Innovative real-time and automated system for infectious diseases diagnosis using optical technology The system’s first application is diagnosis of urinary tract infection (UTI) The system is designed for use by major microbiological laboratories and hospitals, as an alternative to the current
Slide 14: Global microbiology diagnostic market
The global microbiology diagnostic market is expected to total approximately Billion US $ in 2012 million urine cultures are performed each year worldwide of urine cultures return with negative results, after antibiotics have been unnecessarily administered Sources: Venture Planning 2006 Automated M
Slide 15: Pocared: CE certification and FDA trial
Sample collection for the company’s FDA trial will begin after it completes suiting the sample processing procedure to the system’s diagnostic method. During the third quarter of 2011, Elron increased its holding in the company after purchasing another shareholder’s shares and completing another
Slide 16: RDC: Elron and Rafael strategic partnership
Strategic partnership between Elron and Rafael, through a jointly owned subsidiary, that has access to state of the art technologies developed by Rafael and exclusive rights to commercialize them Rafael – Advanced Defense Systems develops & manufactures state of the art armaments for the Israel Defe
Slide 17: Sync-Rx: term sheet for sale at $17.25 million
An investment through RDC, Elron’s and Rafael’s jointly held company. RDC’s holding: 87% The company developed an online image processing system designed to optimize and facilitate coronary catheterizations, from device positioning, to deployment, and post-deployment analysis. FDA-cleared an
Slide 18: SmartWave: implantable atrial defibrillator
Miniature implantable atrial defibrillator, under development. The defibrillator immediately and automatically detects and terminates atrial fibrillation (AF) episodes (a type of irregular heartbeat), without the need for hospitalization. The device delivers electrical pulses to restore the he
Slide 19: No other implantable atrial defibrillator; cost of AF in US
The estimated direct cost of AF in the U.S. in 2008 amounted to approximately Billion US $ There is currently no other implantable atrial defibrillator. American Heart Association: Heart Disease and Stroke Statistics – 2012 Update
Slide 20: CartiHeal: cartilage repair implants
Develops implants for repairing cartilage and osteochondral defects in loadbearing joints, such as the knee and ankle. CartiHeal's first product is indicated for treatment of cartilage defects in the knee. Pre-clinical and clinical trials on the first product have demonstrated the regeneration
Slide 21: Cartilage repair market expected to exceed $3 billion
Million people in the U.S. alone suffer from cartilage injuries The cartilage repair market is expected to exceed $3 billion BioMedGPS, 2012; Medtech Insight, January 2011
Slide 22: Given Imaging Highlights of Q3/2012 Results
The company recently had a meeting with the FDA to discuss the process for market clearance of the PillCam COLON 2 capsule for the visualization of the colon. Based on the meeting, the company plans to submit this product for FDA clearance by the end of the year under the direct de novo route.
Slide 23: Elron Financial Data
ELRON > FINANCIAL DATA Effective Public Holdings ($m) (Market value as of November 11, 2012) Given Imaging 154.8 Other holdings 0.3 Total Public Holdings 155.1 Private Holdings (Book value as of September 30, 2012) Pocared 2.8 BrainsGate 3.4 Other holdings 1 30.2 Total Private Holdings 36.4 Financia
Slide 24: Elron history and track record
Elron was established in 1962 by Uzia Galil in order to develop the Israeli hi-tech industry. In 1975, the company listed on the Tel Aviv Stock Exchange under the symbol ELRN. Over the past five decades, the company has been instrumental in building groundbreaking Israeli hi-tech companies.
Slide 25: Contact: info@elron.com
info@igiron.com
Elron Ventures — Investor Presentation (November 2012) on 6ix